Analysts Set Bio-Rad Laboratories, Inc. (NYSE:BIO) Price Target at $395.20

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) have earned an average rating of “Moderate Buy” from the five research firms that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $395.20.

Several research firms recently commented on BIO. Wells Fargo & Company dropped their price target on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 12th. Royal Bank of Canada reiterated an “outperform” rating and issued a $481.00 price target on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Finally, StockNews.com lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, February 17th.

Institutional Trading of Bio-Rad Laboratories

Institutional investors have recently added to or reduced their stakes in the company. Venturi Wealth Management LLC lifted its stake in Bio-Rad Laboratories by 2,175.0% in the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock worth $30,000 after purchasing an additional 87 shares during the last quarter. GeoWealth Management LLC raised its stake in shares of Bio-Rad Laboratories by 342.9% during the fourth quarter. GeoWealth Management LLC now owns 93 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 72 shares in the last quarter. Gladius Capital Management LP bought a new stake in shares of Bio-Rad Laboratories during the third quarter valued at approximately $32,000. Picton Mahoney Asset Management raised its stake in shares of Bio-Rad Laboratories by 55.6% during the fourth quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 35 shares in the last quarter. Finally, Asset Planning Inc bought a new stake in shares of Bio-Rad Laboratories during the fourth quarter valued at approximately $33,000. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Trading Down 0.4 %

Shares of Bio-Rad Laboratories stock opened at $264.60 on Friday. The firm has a market cap of $7.41 billion, a price-to-earnings ratio of -4.07 and a beta of 0.90. The business has a 50-day moving average price of $327.02 and a 200-day moving average price of $332.52. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories has a twelve month low of $262.11 and a twelve month high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. Equities research analysts anticipate that Bio-Rad Laboratories will post 10.81 EPS for the current fiscal year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.